ClinicalTrials.gg
Active, not recruitingNCT05242471DUET-CDUpdated Nov 4, 2026

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

A Phase 2 interventional study of Guselkumab and Golimumab in Crohn's Disease, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 456 sites in 36 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Updated Nov 4, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
703
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing guselkumab in Crohn Disease — 6 open to participants now, 11 under way, 7 of them phase 3. guselkumab · Crohn Disease.

Enrollment
2nd of 13
703 · median 196
Started
2022
with 2 others
Phase 2
Only one
of the 13
Primary completion
2025-05
later than 2 of 10 live
Registered
4th of 13
by date
Lead sponsor
8 of 13
Janssen Research & Development, LLC

Among the 13 studies testing guselkumab in Crohn Disease, this one is the 2nd largest by enrollment, is one of 3 that started in 2022, is the only one in phase 2, reaches primary completion later than 2 of the 10 other live ones, and was the 4th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 13 studies testing guselkumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing guselkumab in Crohn Disease, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of Crohn's disease (CD) for at least 3 months prior to baseline
  • Confirmed diagnosis of moderate to severe CD as assessed by Crohn'
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
703 participants (actual)

Study arms

  • Placebo comparator
    Group 1: Placebo

    Participants will receive placebo subcutaneously (SC). All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Drug: Placebo

  • Experimental
    Group 2: Guselkumab

    Participants will receive guselkumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: Guselkumab

  • Experimental
    Group 3: Golimumab

    Participants will receive golimumab dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: Golimumab

  • Experimental
    Group 4: JNJ-78934804 (High-dose)

    Participants will receive JNJ-78934804 dose regimen 1 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: JNJ-78934804

  • Experimental
    Group 5: JNJ-78934804 (Mid-dose)

    Participants will receive JNJ-78934804 dose regimen 2 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: JNJ-78934804

  • Experimental
    Group 6: JNJ-78934804 (Low-dose)

    Participants will receive JNJ-78934804 dose regimen 3 SC. All participants who meet inadequate response criteria will be escalated to an active treatment. Participants who are eligible and willing to continue the study intervention that they are receiving at Week 44 may enter the long-term extension.

    Biological: JNJ-78934804

Interventions

  • BiologicalGuselkumab

    Guselkumab will be administered as subcutaneous injection.

  • BiologicalGolimumab

    Golimumab will be administered as subcutaneous injection.

  • BiologicalJNJ-78934804

    JNJ-78934804 will be administered subcutaneously as per defined regimen.

  • DrugPlacebo

    Placebo will be administered as subcutaneous injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Clinical Remission at Week 48

    Percentage of participants with clinical remission at Week 48 will be reported. Clinical remission is based on the Crohn's Disease Activity Index (CDAI).

    Time frame: Week 48

  2. Percentage of Participants with Endoscopic Response at Week 48

    Percentage of participants with endoscopic response at Week 48 will be reported. Endoscopic response is based on change from baseline in the simple endoscopic score for Crohn's disease (SES-CD), as assessed by central endoscopy reading.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants with Patient-reported Outcomes (PRO)-2 Remission at Week 48

    Percentage of participants with PRO-2 remission at Week 48 will be reported. PRO-2 remission is based on the average daily abdominal pain (AP) and stool frequency (SF) scores.

    Time frame: Week 48

  2. Percentage of Participants with Endoscopic Remission at Week 48

    Percentage of participants with endoscopic remission at Week 48 will be reported. Endoscopic remission is based on the SES-CD, as assessed by central endoscopy reading.

    Time frame: Week 48

  3. Percentage of Participants with Corticosteroid-Free Clinical Remission at Week 48

    Percentage of participants with corticosteroid-free (60-day) clinical remission at Week 48 will be reported.

    Time frame: Week 48

  4. Secondary Comparison: Percentage of Participants with Clinical Remission at Week 48

    Percentage of participants with clinical remission at Week 48 will be reported. Clinical remission is based on the Crohn's Disease Activity Index (CDAI).

    Time frame: Week 48

  5. Secondary Comparison: Percentage of Participants with Endoscopic Response at Week 48

    Percentage of participants with endoscopic response at Week 48 will be reported. Endoscopic response is based on change from baseline in the SES-CD, as assessed by central endoscopy reading.

    Time frame: Week 48

  6. Percentage of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

    Time frame: Up to Week 48

  7. Percentage of Participants with Serious Adverse Events (SAEs)

    A SAE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is a suspected transmission of any infectious agent via a medicinal product; is medically important.

    Time frame: Up to Week 48

  8. Clinical Laboratory Parameters Over Time

    Clinical laboratory parameters over time will be reported.

    Time frame: Up to Week 48

  9. Vital Sign Parameters Over Time

    Vital sign parameters over time will be reported.

    Time frame: Up to Week 48

  10. Suicidal Ideation Assessment Using Columbia Suicide Severity Rating Scale (C-SSRS) Score

    The C-SSRS scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Worsening of suicidal ideation is defined as an increase in severity of suicidal ideation from baseline.

    Time frame: Up to Week 48

  11. Serum Concentrations of Guselkumab Over Time

    Serum concentrations of guselkumab over time will be reported. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive method.

    Time frame: Up to Week 48

  12. Serum Concentrations of Golimumab Over Time

    Serum concentrations of golimumab over time will be reported. Serum samples will be analyzed to determine concentrations of golimumab using a validated, specific, and sensitive method.

    Time frame: Up to Week 48

  13. Percentage of Participants with Antibodies to Guselkumab

    Percentage of participants with antibodies to guselkumab will be reported.

    Time frame: Up to Week 48

  14. Titers of Antibodies to Guselkumab

    Titers of antibodies to guselkumab will be reported.

    Time frame: Up to Week 48

  15. Percentage of Participants with Antibodies to Golimumab

    Percentage of participants with antibodies to golimumab will be reported.

    Time frame: Up to Week 48

  16. Titers of Antibodies to Golimumab

    Titers of antibodies to golimumab will be reported.

    Time frame: Up to Week 48

  17. Percentage of Participants with Neutralizing Antibodies to Guselkumab.

    Percentage of participants with neutralizing antibodies to guselkumab will be reported.

    Time frame: Up to Week 48

  18. Percentage of Participants with Neutralizing Antibodies to Golimumab

    Percentage of participants with neutralizing antibodies to golimumab will be reported.

    Time frame: Up to Week 48

07

Study locations

456 sites

Showing the first 100 of 456 sites across 36 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in May 2025, 34 months.

Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 34 months is close to that.

Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2022
First posted
Feb 16, 2022
StartActual
Jul 22, 2022
Primary completionActual
May 23, 2025
CompletionEst.
Nov 5, 2029
Results delay requested
May 21, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (1 India, 1 Israel)
  • Fortis Memorial Research Institute · Gūrgaon, India
  • The Chaim Sheba Medical Center · Tel HaShomer, Israel
Show 2 removed
  • Fortis Memorial Research Institute · Gurgaon, India
  • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
Nov 4, 2026
Show all 2 updates
  1. Nov 4, 2026
    2 sites added, 2 sites removed
    Show 2 added (1 India, 1 Israel)
    • Fortis Memorial Research Institute · Gūrgaon, India
    • The Chaim Sheba Medical Center · Tel HaShomer, Israel
    Show 2 removed
    • Fortis Memorial Research Institute · Gurgaon, India
    • The Chaim Sheba Medical Center · Tel Litwinsky, Israel
    + 1 other change: verification date
  2. Sep 28, 2026
    Minor edits only
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05242471
Responsible party
Sponsor
First posted
Feb 16, 2022
Start date
Jul 22, 2022
Primary completion
May 23, 2025
Completion
Nov 5, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Guselkumab · Golimumab · JNJ-78934804

Start the discussion